Onconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes
(Thomson Reuters ONE) -
NEWTOWN, Pa., May 01, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc.
(NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering
and developing novel products to treat cancer, with a primary focus on
myelodysplastic syndromes, today announced one oral and one poster presentation
at the 14(th) International Symposium on Myelodysplastic Syndromes taking place
May 3-6, 2017 at the Palacios de Congresos de Valencia in Valencia, Spain.
These presentations will be made by the Company's collaborators from the Mount
Sinai School of Medicine and the Cleveland Clinic.
Abstract Details:
Poster Presentation:
Date: May 4(th) through May 6(th)
Time: 8:00 am
Location: Poster Presentation Section
Presenter: Dr. Aziz Nazha - Cleveland Clinic, Cleveland, Ohio
A Validation of a Post-Hypomethylating Agent Failure (HMAF) Prognostic Model in
Myelodysplastic Syndromes (MDS) Patients Treated with Rigosertib versus Best
Supportive Care (BSC) in a Randomized Controlled Phase III trial
Oral Presentation:
Date: Saturday May 6(th)
Time: 8:30 am-10 am
Location: Auditorium 1
Presenter: Dr. Shyamala Navada - Mount Sinai School of Medicine, NYC
Combination of Oral Rigosertib and Injectable Azacitidine In Patients with
Myelodysplastic Syndromes (MDS)
Additional details and content from these presentations will be available on the
Company's website on the day of the presentations.
About Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc. is a Phase 3 stage biopharmaceutical company focused
on discovering and developing novel small molecule drug candidates to treat
cancer, with a primary focus on Myelodysplastic Syndromes (MDS). Rigosertib,
Onconova's lead candidate, is a proprietary Phase 3 small molecule agent, which
blocks cellular signaling by targeting RAS effector pathways. Using a
proprietary chemistry platform, Onconova has created a pipeline of targeted
anti-cancer agents designed to work against specific cellular pathways that are
important in cancer cells, while causing minimal damage to normal
cells. Onconova has three product candidates in clinical trials and several
active pre-clinical programs. Advanced clinical trials with Onconova's lead
compound, rigosertib, are aimed at unmet medical needs of patients with MDS. For
more information, please visit http://www.onconova.com.
GENERAL CONTACT:
http://www.onconova.com/contact/
INVESTOR RELATIONS CONTACT:
Lisa Sher, MBS Value Partners on behalf of Onconova Therapeutics
Lisa.Sher(at)mbsvalue.com / (212) 750-5800
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Onconova Therapeutics via GlobeNewswire
Datum: 01.05.2017 - 14:30 Uhr
Sprache: Deutsch
News-ID 539371
Anzahl Zeichen: 3255
contact information:
Town:
Newtown
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 201 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Onconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes"
steht unter der journalistisch-redaktionellen Verantwortung von
Onconova Therapeutics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
